Colestilan  (Synonyms: MCI-196; Colestimide)

Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research^[1][2].

Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract^[2].
Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats^[3].
Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(C₄H₆N₂.C₃H₅ClO)x

95522-45-5

Solid

Off-white to light brown

CC1=[N+](CC(C)O)C=CN1C.[n].[Cl-]

Room temperature in continental US; may vary elsewhere.

• [1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81.  [Content Brief]

  [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30.  [Content Brief]

  [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.